Raising money in uncertain times: how Splice Bio secured $135 million for its gene therapy play

Raising money in the gene therapy space can be tough right now but, for the right company and with the right team, there is still cash to be found. But how do you connect with investors, how do you get your science in front of the right people, and how do you move from ‘I’m interested’ to ‘I’m signing on the dotted line’?This week I talk with Gerard Caelles, Chief Business Office of Splice Bio, a company that just closed a $135 million series B fundraising round. I quiz him on the practical steps that biotechs need to take to move from a series A to a series B, the key members of the team that pulled the deal together, how to keep existing investors engaged while bringing new money on-board, and how it feels when it is all done. 01:14               Meet Gerard Caelles04:34               The Splice Bio platform12:34               Raising $135 million in uncertain times15:31               Laying the groundwork for a series B18:15               Building a fundraising team20:45               Identifying and approaching new investors22:38               Fundraising challenges in 202526:37               Refining the strategy and pitch29:00               Choosing lead investors 31:59               Keeping existing investors on board34:12               A look behind the scenes 37:52               What’s next for Splice Bio42:10               Learn more about Splice BioInterested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletterTo dive deeper into the topic: Labiotech's 2025 Biotech Funding TrackerThe ABC of biotech startup fundingBudget blues: where are cell and gene therapies heading?